Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Payables: 2014-2024

Historic Payables for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $40.6 million.

  • ImmunityBio's Payables rose 8620.40% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.8 million, marking a year-over-year increase of 94.53%. This contributed to the annual value of $40.6 million for FY2024, which is 4.98% down from last year.
  • Latest data reveals that ImmunityBio reported Payables of $40.6 million as of FY2024, which was down 4.98% from $42.7 million recorded in FY2023.
  • ImmunityBio's Payables' 5-year high stood at $473.7 million during FY2022, with a 5-year trough of $36.8 million in FY2020.
  • Moreover, its 3-year median value for Payables was $42.7 million (2023), whereas its average is $185.7 million.
  • As far as peak fluctuations go, ImmunityBio's Payables soared by 2,002.40% in 2020, and later plummeted by 90.98% in 2023.
  • ImmunityBio's Payables (Yearly) stood at $36.8 million in 2020, then spiked by 853.53% to $350.6 million in 2021, then spiked by 35.11% to $473.7 million in 2022, then slumped by 90.98% to $42.7 million in 2023, then fell by 4.98% to $40.6 million in 2024.